Effect of osteopontin on the mRNA expression of ADAMTS4 and ADAMTS5 in chondrocytes from patients with knee osteoarthritis

Gao,Shu‑Guang; Zeng,Chao; Song,Yang; Tian,Jian; Cheng,Chao; Yang,Tuo; Li,Hui; Zhang,Fang‑Jie; Lei,Guang‑Hua

doi:10.3892/etm.2015.2310

Effect of osteopontin on the mRNA expression of ADAMTS4 and ADAMTS5 in chondrocytes from patients with knee osteoarthritis

Authors:
- Shu‑Guang Gao
- Chao Zeng
- Yang Song
- Jian Tian
- Chao Cheng
- Tuo Yang
- Hui Li
- Fang‑Jie Zhang
- Guang‑Hua Lei
View Affiliations

Affiliations: Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: February 24, 2015 https://doi.org/10.3892/etm.2015.2310
Pages: 1979-1983

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that osteopontin (OPN) levels are elevated in the synovial fluid and articular cartilage, and are associated with the severity of knee osteoarthritis (OA). However, the role of OPN in the pathogenesis of OA has yet to be elucidated. The present study aimed to investigate the effects of OPN on the expression of the aggrecanases, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)4 and ADAMTS5, in human OA chondrocytes, as they serve a key function in aggrecan degradation. Human OA chondrocytes were obtained from the knees of 16 patients with OA, and subsequently cultured in a monolayer. The chondrocytes were divided into three groups, which included the control (no treatment), N‑OPN (treated with 100 ng/ml OPN, the normal circulating OPN concentration) and the H‑OPN groups (treated with 1 µg/ml OPN, a high OPN concentration). Reverse transcription‑quantitative polymerase chain reaction was performed to quantify the relative mRNA expression levels of ADAMTS4, ADAMTS5 and aggrecan in the chondrocytes. The mRNA expression levels of ADAMTS4 were significantly reduced in the N‑OPN and H‑OPN groups when compared with the control group (P<0.0001). In addition, the mRNA expression levels of ADAMTS4 were lower in the H‑OPN group when compared with the N‑OPN group (P<0.001). However, no statistically significant difference was observed in the relative mRNA expression levels of ADAMTS5 among the three groups (P>0.05). Furthermore, the mRNA expression levels of aggrecan were higher in the N‑OPN and H‑OPN groups when compared with the control group (P<0.0001), and a statistically significant difference was observed between the N‑OPN and H‑OPN groups with regard to the mRNA expression of aggrecan (P<0.0001). These results demonstrated that OPN may exert a protective effect in human OA chondrocytes against aggrecan degradation by suppressing the expression of ADAMTS4.

View Figures

View References

1	Bijlsma JW, Berenbaum F and Lafeber FP: Osteoarthritis: an update with relevance for clinical practice. Lancet. 377:2115–2126. 2011. View Article : Google Scholar : PubMed/NCBI
2	Jiang L, Rong J, Zhang Q, et al: Prevalence and associated factors of knee osteoarthritis in a community-based population in Heilongjiang. Northeast China. Rheumatol Int. 32:1189–1195. 2012. View Article : Google Scholar
3	Bobacz K, Erlacher L, Smolen J, Soleiman A and Graninger WB: Chondrocyte number and proteoglycan synthesis in the aging and osteoarthritic human articular cartilage. Ann Rheum Dis. 63:1618–1622. 2004. View Article : Google Scholar : PubMed/NCBI
4	Yatabe T, Mochizuki S, Takizawa M, et al: Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis. 68:1051–1058. 2009. View Article : Google Scholar : PubMed/NCBI
5	Cheung KS, Hashimoto K, Yamada N and Roach HI: Expression of ADAMTS-4 by chondrocytes in the surface zone of human osteoarthritic cartilage is regulated by epigenetic DNA de-methylation. Rheumatol Int. 29:525–534. 2009. View Article : Google Scholar : PubMed/NCBI
6	Larsson S, Englund M, Struglics A and Lohmander LS: Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis. Arthritis Res Ther. 12:R2302010. View Article : Google Scholar : PubMed/NCBI
7	Huang K and Wu LD: Suppression of aggrecanase: a novel protective mechanism of dehydroepiandrosterone in osteoarthritis? Mol Biol Rep. 37:1241–1245. 2010. View Article : Google Scholar : PubMed/NCBI
8	Naito S, Shiomi T, Okada A, et al: Expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic cartilage. Pathol Int. 57:703–711. 2007. View Article : Google Scholar : PubMed/NCBI
9	Verma P and Dalal K: ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis. J Cell Biochem. 112:3507–3514. 2011. View Article : Google Scholar : PubMed/NCBI
10	Matsui Y, Iwasaki N, Kon S, et al: Accelerated development of aging-associated and instability-induced osteoarthritis in osteopontin-deficient mice. Arthritis Rheum. 60:2362–2371. 2009. View Article : Google Scholar : PubMed/NCBI
11	Pullig O, Weseloh G, Gauer S and Swoboda B: Osteopontin is expressed by adult human osteoarthritic chondrocytes: protein and mRNA analysis of normal and osteoarthritic cartilage. Matrix Biol. 19:245–255. 2000. View Article : Google Scholar : PubMed/NCBI
12	Gao SG, Li KH, Zeng KB, Tu M, Xu M and Lei GH: Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage. 18:82–87. 2010. View Article : Google Scholar : PubMed/NCBI
13	Sharif SA, Du X, Myles T, et al: Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum. 60:2902–2912. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kon S, Ikesue M, Kimura C, et al: Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J Exp Med. 205:25–33. 2008. View Article : Google Scholar : PubMed/NCBI
15	Altman R, Asch E, Bloch D, et al: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 29:1039–1049. 1986. View Article : Google Scholar : PubMed/NCBI
16	Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM and Lee FY: Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol. 60:225–230. 2009. View Article : Google Scholar : PubMed/NCBI
17	Denhardt DT, Giachelli CM and Rittling SR: Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol. 41:723–749. 2001. View Article : Google Scholar : PubMed/NCBI
18	Ramaiah SK and Rittling S: Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury. Expert Opin Drug Metab Toxicol. 3:519–526. 2007. View Article : Google Scholar : PubMed/NCBI
19	Ermakov S, Leonov A, Trofimov S, Malkin I and Livshits G: Quantitative genetic study of the circulating osteopontin in community-selected families. Osteoporos Int. 22:2261–2271. 2011. View Article : Google Scholar : PubMed/NCBI
20	Glasson SS, Askew R, Sheppard B, et al: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 434:644–648. 2005. View Article : Google Scholar : PubMed/NCBI
21	Stanton H, Rogerson FM, East CJ, et al: ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 434:648–652. 2005. View Article : Google Scholar : PubMed/NCBI
22	Koshy PJ, Lundy CJ, Rowan AD, et al: The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum. 46:961–967. 2002. View Article : Google Scholar : PubMed/NCBI
23	Moulharat N, Lesur C, Thomas M, et al: Effects of transforming growth factor-beta on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro. Osteoarthritis Cartilage. 12:296–305. 2004. View Article : Google Scholar : PubMed/NCBI
24	Hui W, Barksby HE, Young DA, et al: Oncostatin M in combination with tumour necrosis factor alpha induces a chondrocyte membrane-associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or-2. Ann Rheum Dis. 64:1624–1632. 2005. View Article : Google Scholar : PubMed/NCBI
25	Tortorella MD, Malfait AM, Deccico C and Arner E: The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage. 9:539–552. 2001. View Article : Google Scholar : PubMed/NCBI
26	Ohshima S, Yamaguchi N, Nishioka K, et al: Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol. 29:2061–2067. 2002.PubMed/NCBI
27	Petrow PK, Hummel KM, Schedel J, et al: Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum. 43:1597–1605. 2000. View Article : Google Scholar : PubMed/NCBI
28	Standal T, Borset M and Sundan A: Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol. 26:179–184. 2004.PubMed/NCBI
29	Attur MG, Dave MN, Stuchin S, Kowalski AJ, Steiner G, Abramson SB, Denhardt DT and Amin AR: Osteopontin: An intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum. 44:578–584. 2001. View Article : Google Scholar : PubMed/NCBI
30	Xu G, Nie H, Li N, et al: Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest. 115:1060–1067. 2005. View Article : Google Scholar : PubMed/NCBI
31	Okamura N, Hasegawa M, Nakoshi Y, et al: Deficiency of tenascin-C delays articular cartilage repair in mice. Osteoarthritis Cartilage. 18:839–848. 2010. View Article : Google Scholar : PubMed/NCBI
32	Nakoshi Y, Hasegawa M, Akeda K, Iino T, Sudo A, Yoshida T and Uchida A: Distribution and role of tenascin-C in human osteoarthritic cartilage. J Orthop Sci. 15:666–673. 2010. View Article : Google Scholar : PubMed/NCBI
33	Gao SG, Cheng L, Zeng C, et al: Usefulness of specific OA biomarkers, thrombin-cleaved osteopontin, in the posterior cruciate ligament OA rabbit model. Osteoarthritis Cartilage. 21:144–150. 2013. View Article : Google Scholar : PubMed/NCBI
34	Cook AC, Chambers AF, Turley EA and Tuck AB: Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem. 281:24381–24389. 2006. View Article : Google Scholar : PubMed/NCBI
35	Tajima K, Ohashi R, Sekido Y, Hida T, Nara T, Hashimoto M, Iwakami S, Minakata K, Yae T, Takahashi F, et al: Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 29:1941–1951. 2010. View Article : Google Scholar : PubMed/NCBI
36	Ariyoshi W, Takahashi N, Hida D, Knudson CB and Knudson W: Mechanisms involved in enhancement of the expression and function of aggrecanases by hyaluronan oligosaccharides. Arthritis Rheum. 64:187–197. 2012. View Article : Google Scholar : PubMed/NCBI